
Joaquin Arenas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3773302/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Elevated glutamate and decreased glutamine levels in the cerebrospinal fluid of patients with MELAS syndrome. Journal of Neurology, 2022, 269, 3238-3248.	3.6	7
2	Apoptosis-Inducing Factor Deficiency Induces Tissue-Specific Alterations in Autophagy: Insights from a Preclinical Model of Mitochondrial Disease and Exercise Training Effects. Antioxidants, 2022, 11, 510.	5.1	0
3	Long-Term Exercise Intervention in Patients with McArdle Disease: Clinical and Aerobic Fitness Benefits. Medicine and Science in Sports and Exercise, 2022, 54, 1231-1241.	0.4	7
4	Clinical, Histological, and Genetic Features of 25 Patients with Autosomal Dominant Progressive External Ophthalmoplegia (ad-PEO)/PEO-Plus Due to TWNK Mutations. Journal of Clinical Medicine, 2022, 11, 22.	2.4	5
5	Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies. Genes, 2022, 13, 74.	2.4	4
6	Identification of Potential Muscle Biomarkers in McArdle Disease: Insights from Muscle Proteome Analysis. International Journal of Molecular Sciences, 2022, 23, 4650.	4.1	0
7	Metrics of Progression and Prognosis in Untreated Adults With Thymidine Kinase 2 Deficiency: An Observational Study. Neuromuscular Disorders, 2022, , .	0.6	2
8	Physical exercise and epicardial adipose tissue: A systematic review and metaâ€analysis of randomized controlled trials. Obesity Reviews, 2021, 22, e13103.	6.5	24
9	Response to Letter to the Editor. Obesity Reviews, 2021, 22, e13253.	6.5	0
10	Plasma Gelsolin Reinforces the Diagnostic Value of FGF-21 and GDF-15 for Mitochondrial Disorders. International Journal of Molecular Sciences, 2021, 22, 6396.	4.1	8
11	SILAC-based complexome profiling dissects the structural organization of the human respiratory supercomplexes in SCAFIKO cells. Biochimica Et Biophysica Acta - Bioenergetics, 2021, 1862, 148414.	1.0	15
12	Regulation of Mitochondrial Function by the Actin Cytoskeleton. Frontiers in Cell and Developmental Biology, 2021, 9, 795838.	3.7	28
13	Multiple pathways coordinate assembly of human mitochondrial complex IV and stabilization of respiratory supercomplexes. EMBO Journal, 2020, 39, e103912.	7.8	54
14	Altered Expression Ratio of Actin-Binding Gelsolin Isoforms Is a Novel Hallmark of Mitochondrial OXPHOS Dysfunction. Cells, 2020, 9, 1922.	4.1	11
15	Exercise Training and Neurodegeneration in Mitochondrial Disorders: Insights From the Harlequin Mouse. Frontiers in Physiology, 2020, 11, 594223.	2.8	4
16	Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models. International Journal of Molecular Sciences, 2020, 21, 9621.	4.1	13
17	Sex Differences and the Influence of an Active Lifestyle on Adiposity in Patients with McArdle Disease. International Journal of Environmental Research and Public Health, 2020, 17, 4334.	2.6	2
18	Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia. Journal of Medical Genetics, 2020, 57, 643-646.	3.2	21

#	Article	IF	CITATIONS
19	Generation of the iPSC line IISHDOi007-A from peripheral blood mononuclear cells from a patient with McArdle disease harbouring the mutation c.2392ÂTÂ>ÂC; p.Trp798Arg. Stem Cell Research, 2020, 49, 102108.	0.7	1
20	Physical Exercise and Mitochondrial Disease: Insights From a Mouse Model. Frontiers in Neurology, 2019, 10, 790.	2.4	15
21	Novel ATAD3A recessive mutation associated to fatal cerebellar hypoplasia with multiorgan involvement and mitochondrial structural abnormalities. Molecular Genetics and Metabolism, 2019, 128, 452-462.	1.1	23
22	Exercise Benefits in Pulmonary Hypertension. Journal of the American College of Cardiology, 2019, 73, 2906-2907.	2.8	5
23	Late-onset thymidine kinase 2 deficiency: a review of 18 cases. Orphanet Journal of Rare Diseases, 2019, 14, 100.	2.7	29
24	Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model. Scientific Reports, 2019, 9, 5116.	3.3	11
25	Absence of p.R50X Pygm read-through in McArdle disease cellular models. DMM Disease Models and Mechanisms, 2019, 13, .	2.4	4
26	Muscle molecular adaptations to endurance exercise training are conditioned by glycogen availability: a proteomicsâ€based analysis in the McArdle mouse model. Journal of Physiology, 2018, 596, 1035-1061.	2.9	26
27	Health Benefits of an Innovative Exercise Program for Mitochondrial Disorders. Medicine and Science in Sports and Exercise, 2018, 50, 1142-1151.	0.4	16
28	A New Condition in McArdle Disease. Medicine and Science in Sports and Exercise, 2018, 50, 3-10.	0.4	9
29	Las enfermedades raras en las patologÃas neurometabólicas. Arbor, 2018, 194, 461.	0.3	0
30	Manifesting heterozygotes in McArdle disease: a myth or a reality—role of statins. Journal of Inherited Metabolic Disease, 2018, 41, 1027-1035.	3.6	4
31	Missense mutations have unexpected consequences: The McArdle disease paradigm. Human Mutation, 2018, 39, 1338-1343.	2.5	13
32	Respiratory chain enzyme deficiency induces mitochondrial location of actin-binding gelsolin to modulate the oligomerization of VDAC complexes and cell survival. Human Molecular Genetics, 2017, 26, 2493-2506.	2.9	13
33	Low <i>versus</i> high carbohydrates in the diet of the worldâ€class athlete: insights from McArdle's disease. Journal of Physiology, 2017, 595, 2991-2992.	2.9	1
34	Myopathic mtDNA Depletion Syndrome Due to Mutation in TK2 Gene. Pediatric and Developmental Pathology, 2017, 20, 416-420.	1.0	7
35	Muscle fiber type proportion and size is not altered in mcardle disease. Muscle and Nerve, 2017, 55, 916-918.	2.2	4
36	Genotypic and phenotypic features of all Spanish patients with McArdle disease: a 2016 update. BMC Genomics, 2017, 18, 819.	2.8	53

#	Article	IF	CITATIONS
37	Muscle Signaling in Exercise Intolerance. Medicine and Science in Sports and Exercise, 2016, 48, 1448-1458.	0.4	13
38	Secondary coenzyme Q 10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. Mitochondrion, 2016, 30, 51-58.	3.4	70
39	A milder phenotype of megaconial congenital muscular dystrophy due to a novel <i>CHKB</i> mutation. Muscle and Nerve, 2016, 54, 806-808.	2.2	3
40	Genes and exercise intolerance: insights from McArdle disease. Physiological Genomics, 2016, 48, 93-100.	2.3	15
41	COX7A2L Is a Mitochondrial Complex III Binding Protein that Stabilizes the III2+IV Supercomplex without Affecting Respirasome Formation. Cell Reports, 2016, 16, 2387-2398.	6.4	93
42	New ATP8A2 gene mutations associated with a novel syndrome: encephalopathy, intellectual disability, severe hypotonia, chorea and optic atrophy. Neurogenetics, 2016, 17, 259-263.	1.4	36
43	Assessment of resting energy expenditure in pediatric mitochondrial diseases with indirect calorimetry. Clinical Nutrition, 2016, 35, 1484-1489.	5.0	8
44	Exercise and Preexercise Nutrition as Treatment for McArdle Disease. Medicine and Science in Sports and Exercise, 2016, 48, 673-679.	0.4	20
45	Taking advantage of an old concept, "illegitimate transcriptionâ€; for a proposed novel method of genetic diagnosis of McArdle disease. Genetics in Medicine, 2016, 18, 1128-1135.	2.4	9
46	First missense mutation outside of SERAC1 lipase domain affecting intracellular cholesterol trafficking. Neurogenetics, 2016, 17, 51-56.	1.4	7
47	Congenital neurogenic muscular atrophy in megaconial myopathy due to a mutation in CHKB gene. Brain and Development, 2016, 38, 167-172.	1.1	16
48	Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease. Current Pharmaceutical Design, 2016, 22, 2657-2663.	1.9	2
49	A novel RRM2B gene variant associated with Telbivudine-induced mitochondrial myopathy. Journal of the Neurological Sciences, 2015, 358, 481-483.	0.6	7
50	McArdle Disease: Update of Reported Mutations and Polymorphisms in the <i>PYGM</i> Gene. Human Mutation, 2015, 36, 669-678.	2.5	66
51	Minimal symptoms in McArdle disease: A real <i>PYGM</i> genotype effect?. Muscle and Nerve, 2015, 52, 1136-1137.	2.2	1
52	Next-generation sequencing to estimate the prevalence of a great unknown: McArdle disease. Genetics in Medicine, 2015, 17, 679-680.	2.4	13
53	Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model. Journal of Physiology, 2015, 593, 2693-2706.	2.9	17
54	Sodium valproate increases the brain isoform of glycogen phosphorylase: looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture <i>in vitro</i> . DMM Disease Models and Mechanisms, 2015, 8, 467-472.	2.4	19

Joaquin Arenas

#	Article	IF	CITATIONS
55	Differential proteomic profiling unveils new molecular mechanisms associated with mitochondrial complex III deficiency. Journal of Proteomics, 2015, 113, 38-56.	2.4	21
56	Follow-up of folinic acid supplementation for patients with cerebral folate deficiency and Kearns-Sayre syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 217.	2.7	39
57	Exome sequencing identifies a CHKB mutation in Spanish patient with Megaconial Congenital Muscular Dystrophy and mtDNA depletion. European Journal of Paediatric Neurology, 2014, 18, 796-800.	1.6	21
58	Bulk autophagy, but not mitophagy, is increased in cellular model of mitochondrial disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1059-1070.	3.8	29
59	McArdle disease does not affect skeletal muscle fibre type profiles in humans. Biology Open, 2014, 3, 1224-1227.	1.2	8
60	Nitric oxide compounds have different effects profiles on human articular chondrocyte metabolism. Arthritis Research and Therapy, 2013, 15, R115.	3.5	38
61	A new mutation in the gene encoding mitochondrial seryl-tRNA synthetase as a cause of HUPRA syndrome. BMC Nephrology, 2013, 14, 195.	1.8	31
62	Whole-Exome Sequencing Identifies a Variant of the Mitochondrial <i>MT-ND1</i> Gene Associated with Epileptic Encephalopathy: West Syndrome Evolving to Lennox-Gastaut Syndrome. Human Mutation, 2013, 34, 1623-1627.	2.5	25
63	Mitochondrial Complex III Deficiency of Nuclear Origin:. , 2013, , 219-238.		0
64	Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease. Brain, 2012, 135, 2048-2057.	7.6	48
65	Mitochondrial tRNA valine as a recurrent target for mutations involved in mitochondrial cardiomyopathies. Mitochondrion, 2012, 12, 357-362.	3.4	15
66	Clinical and cellular consequences of the mutation m.12300G>A in the mitochondrial tRNALeu(CUN) gene. Mitochondrion, 2012, 12, 288-293.	3.4	6
67	Mitochondrial Complex I Plays an Essential Role in Human Respirasome Assembly. Cell Metabolism, 2012, 15, 324-335.	16.2	234
68	Mitochondrial respiratory chain dysfunction: Implications in neurodegeneration. Free Radical Biology and Medicine, 2012, 53, 595-609.	2.9	132
69	Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 322-328.	1.9	114
70	A Transcriptomic Approach to Search for Novel Phenotypic Regulators in McArdle Disease. PLoS ONE, 2012, 7, e31718.	2.5	22
71	Are mitochondrial haplogroups associated with extreme longevity? A study on a Spanish cohort. Age, 2012, 34, 227-233.	3.0	22
72	Are mitochondrial haplogroups associated with elite athletic status? A study on a Spanish cohort. Mitochondrion, 2011, 11, 905-908.	3.4	20

#	Article	IF	CITATIONS
73	Effect of nitric oxide on mitochondrial activity of human synovial cells. BMC Musculoskeletal Disorders, 2011, 12, 42.	1.9	50
74	Strenuous endurance exercise improves life expectancy: it's in our genes. British Journal of Sports Medicine, 2011, 45, 159-161.	6.7	43
75	Are elite endurance athletes genetically predisposed to lower disease risk?. Physiological Genomics, 2010, 41, 82-90.	2.3	21
76	Excessive skeletal muscle recruitment during strenuous exercise in McArdle patients. European Journal of Applied Physiology, 2010, 110, 1047-1055.	2.5	17
77	Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease. BMC Neurology, 2010, 10, 95.	1.8	37
78	Cellular pathophysiological consequences of BCS1L mutations in mitochondrial complex III enzyme deficiency. Human Mutation, 2010, 31, 930-941.	2.5	61
79	Impact of the Mitochondrial Genetic Background in Complex III Deficiency. PLoS ONE, 2010, 5, e12801.	2.5	34
80	Expression of Glycogen Phosphorylase Isoforms in Cultured Muscle from Patients with McArdle's Disease Carrying the p.R771PfsX33 PYGM Mutation. PLoS ONE, 2010, 5, e13164.	2.5	12
81	World-class performance in lightweight rowing: is it genetically influenced? A comparison with cyclists, runners and non-athletes. British Journal of Sports Medicine, 2010, 44, 898-901.	6.7	71
82	Marked mitochondrial DNA depletion associated with a novel SUCLG1 gene mutation resulting in lethal neonatal acidosis, multi-organ failure, and interrupted aortic arch. Mitochondrion, 2010, 10, 362-368.	3.4	29
83	Infantile mitochondrial encephalomyopathy with unusual phenotype caused by a novel BCS1L mutation in an isolated complex III-deficient patient. Neuromuscular Disorders, 2009, 19, 143-146.	0.6	44
84	Does the K153R variant of the myostatin gene influence the clinical presentation of women with McArdle disease?. Neuromuscular Disorders, 2009, 19, 220-222.	0.6	6
85	The second wind phenomenon in very young McArdle's patients. Neuromuscular Disorders, 2009, 19, 403-405.	0.6	9
86	Pathogenic mutations in the 5′ untranslated region of BCS1L mRNA in mitochondrial complex III deficiency. Mitochondrion, 2009, 9, 299-305.	3.4	29
87	Mitochondrial Disorders Due to Nuclear OXPHOS Gene Defects. Advances in Experimental Medicine and Biology, 2009, 652, 85-116.	1.6	9
88	Mitochondrial Encephalomyopathies in Children. Part I: Conventional MR Imaging Findings. Current Medical Imaging, 2009, 5, 85-99.	0.8	1
89	Mitochondrial Encephalomyopathies in Children. Part II: Advanced MR Tools and the Importance for its Early Recognition in the Acute Clinical Setting. Current Medical Imaging, 2009, 5, 100-109.	0.8	0
90	C34T mutation of the AMPD1 gene in an elite white runner. BMJ Case Reports, 2009, 2009, bcr0720080535-bcr0720080535.	0.5	8

#	Article	IF	CITATIONS
91	Expression of the muscle glycogen phosphorylase gene in patients with McArdle disease: the role of nonsense-mediated mRNA decay. Human Mutation, 2008, 29, 277-283.	2.5	38
92	Mitochondrial DNA haplogroups: Role in the prevalence and severity of knee osteoarthritis. Arthritis and Rheumatism, 2008, 58, 2387-2396.	6.7	96
93	McArdle disease: Another systemic low-inflammation disorder?. Neuroscience Letters, 2008, 431, 106-111.	2.1	9
94	One-Year Follow-Up in a Child With McArdle Disease: Exercise is Medicine. Pediatric Neurology, 2008, 38, 133-136.	2.1	17
95	McArdle disease: what do neurologists need to know?. Nature Clinical Practice Neurology, 2008, 4, 568-577.	2.5	195
96	OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain, 2008, 131, 338-351.	7.6	454
97	Novel mutations in patients with McArdle disease by analysis of skeletal muscle mRNA. Journal of Medical Genetics, 2008, 46, 198-202.	3.2	20
98	Mitochondrial DNA background modulates the assembly kinetics of OXPHOS complexes in a cellular model of mitochondrial disease. Human Molecular Genetics, 2008, 17, 4001-4011.	2.9	140
99	What isn't taught in medical schools: the William Wordsworth lesson. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 372-374.	3.3	6
100	The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease. British Journal of Sports Medicine, 2007, 42, 134-140.	6.7	19
101	Exercise Capacity in a Child With McArdle Disease. Journal of Child Neurology, 2007, 22, 880-882.	1.4	15
102	Favorable Responses to Acute and Chronic Exercise in McArdle Patients. Clinical Journal of Sport Medicine, 2007, 17, 297-303.	1.8	85
103	The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle's disease. Neuromuscular Disorders, 2007, 17, 603-610.	0.6	32
104	Mild ocular myopathy associated with a novel mutation in mitochondrial twinkle helicase. Neuromuscular Disorders, 2007, 17, 677-680.	0.6	14
105	Genotype modulators of clinical severity in McArdle disease. Neuroscience Letters, 2007, 422, 217-222.	2.1	40
106	X-linkedNDUFA1gene mutations associated with mitochondrial encephalomyopathy. Annals of Neurology, 2007, 61, 73-83.	5.3	118
107	A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Human Mutation, 2007, 28, 203-204.	2.5	54
108	Double trouble (McArdle's disease and myasthenia gravis): How can exercise help?. Muscle and Nerve, 2007, 35, 125-128.	2.2	25

#	Article	IF	CITATIONS
109	Human mitochondrial pyrophosphatase: cDNA cloning and analysis of the gene in patients with mtDNA depletion syndromes. Genomics, 2006, 87, 410-416.	2.9	22
110	Oxidative Stress in Skin Fibroblasts Cultures of Patients with Huntington's Disease. Neurochemical Research, 2006, 31, 1103-1109.	3.3	57
111	Mitochondrial activity is modulated by TNFα and IL-1β in normal human chondrocyte cells. Osteoarthritis and Cartilage, 2006, 14, 1011-1022.	1.3	121
112	Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. British Journal of Sports Medicine, 2006, 40, 719-722.	6.7	53
113	Association of Novel POLGMutations and Multiple Mitochondrial DNA Deletions With Variable Clinical Phenotypes in a Spanish Population. Archives of Neurology, 2006, 63, 107.	4.5	57
114	Can patients with McArdle's disease run? * Commentary. British Journal of Sports Medicine, 2006, 41, 53-54.	6.7	19
115	Novel Mutation in the PYGM Gene Resulting in McArdle Disease. Archives of Neurology, 2006, 63, 1782.	4.5	9
116	Exercise capacity in a 78 year old patient with McArdle's disease: it is never too late to start exercising * Commentary. British Journal of Sports Medicine, 2006, 40, 725-726.	6.7	8
117	Increased mitochondrial respiratory chain enzyme activities correlate with minor extent of liver damage in mice suffering from erythropoietic protoporphyria. Experimental Dermatology, 2005, 14, 26-33.	2.9	14
118	Exercise training in mitochondrial myopathy: A randomized controlled trial. Muscle and Nerve, 2005, 32, 342-350.	2.2	87
119	Renal pathology in children with mitochondrial diseases. Pediatric Nephrology, 2005, 20, 1299-1305.	1.7	105
120	Specific correlation between the wobble modification deficiency in mutant tRNAs and the clinical features of a human mitochondrial disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7127-7132.	7.1	147
121	Leigh Syndrome Associated With Mitochondrial Complex I Deficiency Due to a Novel Mutation in the NDUFS1 Gene. Archives of Neurology, 2005, 62, 659.	4.5	71
122	Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: does this mutation impair performance?. Journal of Applied Physiology, 2005, 98, 2108-2112.	2.5	76
123	Comparative analysis of the pathogenic mechanisms associated with the G8363A and A8296G mutations in the mitochondrial tRNALys gene. Biochemical Journal, 2005, 387, 773-778.	3.7	27
124	Free radicals-mediated damage in transmitochondrial cells harboring the T14487C mutation in the ND6 gene of mtDNA. FEBS Letters, 2005, 579, 6909-6913.	2.8	32
125	Increased muscle nucleoside levels associated with a novel frameshift mutation in the thymidine phosphorylase gene in a Spanish patient with MNGIE. Neuromuscular Disorders, 2005, 15, 775-778.	0.6	18
126	Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes. Annals of the Rheumatic Diseases, 2004, 64, 388-395.	0.9	122

#	Article	IF	CITATIONS
127	Molecular Analysis of Myophosphorylase Deficiency in Dutch Patients with McArdle's Disease. Annals of Human Genetics, 2004, 68, 17-22.	0.8	26
128	Apolipoprotein E polymorphism and carotid atherosclerosis in patients with coronary disease. International Journal of Cardiology, 2004, 94, 209-212.	1.7	17
129	Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003, 38, 999-1007.	7.3	585
130	Two novel mutations in the muscle glycogen phosphorylase gene in McArdle's disease. Muscle and Nerve, 2003, 28, 380-382.	2.2	9
131	Prevalence and progression of mitochondrial diseases: A study of 50 patients. Muscle and Nerve, 2003, 28, 690-695.	2.2	44
132	The V368i mutation in Twinkle does not segregate with adPEO. Annals of Neurology, 2003, 53, 278-278.	5.3	7
133	Mitochondrial respiratory activity is altered in osteoarthritic human articular chondrocytes. Arthritis and Rheumatism, 2003, 48, 700-708.	6.7	195
134	Unusual clinical findings and Complex III deficiency in a family with myotonic dystrophy. Journal of the Neurological Sciences, 2003, 208, 87-91.	0.6	7
135	Mitochondrial DNA Haplogroups Do Not Play a Role in the Variable Phenotypic Presentation of the A3243G Mutation. American Journal of Human Genetics, 2003, 72, 1005-1012.	6.2	47
136	Reactive oxygen species mediate the down-regulation of mitochondrial transcripts and proteins by tumour necrosis factor-alpha in L929 cells. Biochemical Journal, 2003, 370, 609-619.	3.7	20
137	Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003, 38, 999-1007.	7.3	358
138	Amylase Levels in Pleural Effusions. Chest, 2002, 121, 470-474.	0.8	56
139	Sirolimus Does Not Exhibit Nephrotoxicity Compared to Cyclosporine in Renal Transplant Recipients. American Journal of Transplantation, 2002, 2, 436-442.	4.7	178
140	Cosegregation of the mitochondrial DNA A1555G and G4309A mutations results in deafness and mitochondrial myopathy. Muscle and Nerve, 2002, 25, 185-188.	2.2	12
141	The A8296G mtDNA mutation associated with several mitochondrial diseases does not cause mitochondrial dysfunction in cybrid cell lines. Human Mutation, 2002, 19, 234-239.	2.5	15
142	Expression of glucose transporter-2, glucokinase and mitochondrial glycerolphosphate dehydrogenase in pancreatic islets during rat ontogenesis. FEBS Journal, 2002, 269, 119-127.	0.2	15
143	Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats. Journal of Neurochemistry, 2001, 78, 1054-1063.	3.9	50
144	Resolution of a mispaired secondary structure intermediate could account for a novel micro-insertion/deletion (387 insA/del 8 bp) in the PYGM gene causing McArdle's disease. Clinical Genetics, 2001, 59, 48-51.	2.0	15

#	Article	IF	CITATIONS
145	Early onset multisystem mitochondrial disorder caused by a nonsense mutation in the mitochondrial DNACytochrome C oxidase Ilgene. Annals of Neurology, 2001, 50, 409-413.	5.3	51
146	Molecular heterogeneity of myophosphorylase deficiency (Mcardle's disease): A genotype-phenotype correlation study. Annals of Neurology, 2001, 50, 574-581.	5.3	86
147	Mitochondrial myopathy, cardiomyopathy and psychiatric illness in a Spanish family harbouring the mtDNA 3303C > T mutation. Journal of Inherited Metabolic Disease, 2001, 24, 685-687.	3.6	18
148	Congenital Hydranencephalic-Hydrocephalic Syndrome With Proliferative Vasculopathy: A Possible Relation With Mitochondrial Dysfunction. Journal of Child Neurology, 2001, 16, 858-862.	1.4	24
149	Molecular heterogeneity of myophosphorylase deficiency (Mcardle's disease): A genotype-phenotype correlation study. Annals of Neurology, 2001, 50, 574.	5.3	1
150	A missense mutation W797R in the myophosphorylase gene in a Spanish patient with McArdle's disease. Muscle and Nerve, 2000, 23, 129-131.	2.2	14
151	Lipomatosis, proximal myopathy, and the mitochondrial 8344 mutation. A lipid storage myopathy?. , 2000, 23, 538-542.		44
152	Two homozygous mutations (R193W and 794/795 delAA) in the myophosphorylase gene in a patient with McArdle's disease. Human Mutation, 2000, 15, 294-294.	2.5	55
153	Molecular analysis of Spanish patients with AMP deaminase deficiency. Muscle and Nerve, 2000, 23, 1175-1178.	2.2	21
154	Identification of novel mutations in Spanish patients with muscle carnitine palmitoyltransferase II deficiency. Human Mutation, 2000, 15, 579-580.	2.5	27
155	Congenital Hydranencephalic-Hydrocephalic Syndrome Associated With Mitochondrial Dysfunction. Journal of Child Neurology, 1999, 14, 131-135.	1.4	22
156	Cerebrospinal Fluid Nitrate Levels in Patients with Multiple Sclerosis. European Neurology, 1999, 41, 44-47.	1.4	22
157	Serum levels of βâ€carotene, αâ€carotene and vitamin A in patients with Alzheimer's disease. European Journal of Neurology, 1999, 6, 495-497.	3.3	71
158	Slow segregation and rapid shift to homoplasmy coexist in a family with the T8993>G mutation. Journal of Inherited Metabolic Disease, 1999, 22, 939-940.	3.6	2
159	Molecular analysis in spanish patients with muscle carnitine palmitoyltransferase deficiency. , 1999, 22, 941-943.		22
160	About the "Pathological―Role of the mtDNA T3308C Mutation…. American Journal of Human Genetics, 1999, 65, 1457-1459.	6.2	30
161	Complex I Defect in muscle from patients with Huntington's disease. Annals of Neurology, 1998, 43, 397-400.	5.3	154
162	Mitochondrial gene expression and respiratory enzyme activities in cardiac diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1406, 85-90.	3.8	17

#	Article	IF	CITATIONS
163	Cerebrospinal fluid carnitine levels in patients with Parkinson's disease. Journal of the Neurological Sciences, 1997, 145, 183-185.	0.6	11
164	Association of genetically proven deficiencies of myophosphorylase and AMP deaminase: a second case of â€~double trouble'. Neuromuscular Disorders, 1997, 7, 387-389.	0.6	23
165	Syndrome of encephalopathy, petechiae, and ethylmalonic aciduria. Pediatric Neurology, 1997, 17, 165-170.	2.1	48
166	The association of Acetyl-l-Carnitine with glucose and lipid metabolism in human muscle in vivo: The effect of hyperinsulinemia. Metabolism: Clinical and Experimental, 1997, 46, 1454-1457.	3.4	7
167	Diffuse Fatty Liver in Familial Heterozygous Hypobetalipoproteinemia. Journal of Clinical Gastroenterology, 1997, 25, 379-382.	2.2	32
168	Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. Journal of the Neurological Sciences, 1996, 141, 39-44.	0.6	56
169	Reduced carnitine palmitoyl transferase activity and altered acyl-trafficking in red blood cells from hemodialysis patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1315, 37-39.	3.8	7
170	Cyclosporine Nephrotoxicity and Rejection Crisis: Diagnosis by Urinary Enzyme Excretion. Nephron, 1996, 72, 402-406.	1.8	12
171	Multiple deletions of mitochondrial DNA in muscle from a patient with benign progressive external ophthalmoplegia. Journal of Inherited Metabolic Disease, 1996, 19, 366-367.	3.6	2
172	Sporadic MERRF/MELAS overlap syndrome associated with the 3243 tRNALeu(UUR) mutation of mitochondrial DNA. , 1996, 19, 187-190.		36
173	Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy. Arthritis and Rheumatism, 1996, 39, 1869-1874.	6.7	10
174	Leber's Congenital Amaurosis Associated With Mitochondrial Dysfunction. Journal of Child Neurology, 1996, 11, 108-111.	1.4	4
175	Serum levels of nitrates in focal cerebral ischemia. European Journal of Neurology, 1995, 2, 225-227.	3.3	3
176	Mitochondrial DNA deletion in a patient with mitochondrial myopathy, lactic acidosis, and stroke-like episodes (MELAS) and Fanconi's syndrome. Pediatric Neurology, 1995, 13, 69-72.	2.1	51
177	Letters to the editor. Muscle and Nerve, 1994, 17, 1225-1238.	2.2	2
178	Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy. Annals of Neurology, 1994, 36, 680-680.	5.3	8
179	Plasma levels of nitrates in patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 127, 87-89.	0.6	16
180	Effects ofl-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Letters, 1994, 341, 91-93.	2.8	44

#	Article	IF	CITATIONS
181	Plasma carnitine insufficiency and effectiveness of <scp>L</scp> arnitine therapy in patients with mitochondril myopathy. Muscle and Nerve, 1993, 16, 150-153.	2.2	91
182	Muscle carnitine deficiency and lipid storage myopathy in patients with mitochondrial myopathy. Muscle and Nerve, 1993, 16, 778-781.	2.2	39
183	Respiratory chain enzymes in muscle of endurance athletes: Effect of L-carnitine. Biochemical and Biophysical Research Communications, 1992, 188, 102-107.	2.1	40
184	Letters to the editor. Muscle and Nerve, 1992, 15, 1055-1059.	2.2	2
185	Nephrotic Proteinuria Without Hypoalbuminemia: Clinical Characteristics and Response to Angiotensin-Converting Enzyme Inhibition. American Journal of Kidney Diseases, 1991, 17, 330-338.	1.9	75
186	Macro creatine kinase type 2 in a patient with prostatic carcinoma. Clinica Chimica Acta, 1991, 200, 53-56.	1.1	4